Company Profiles

BluSense

Tue, 15 Jan 2019 11:13:39 GMT

The BluSense technology enables the accurate diagnosis of dengue and zika using a single drop of blood.

Combining biomarker quantification with portability, affordability and ease of use, BluSense point-of-care products are designed for helping healthcare organizations to increase their diagnostics capacity, and to monitor, control and manage virus outbreaks.

For more info, go to https://www.blusense-diagnostics.com/

Lifandis - Unlocking the secrets of disease

Wed, 09 Apr 2014 14:29:18 GMT

Lifandis links the industry to a wealth of biological samples from the HUNT studies. It is the entry point to a unique set of biological samples and extensive clinical and longitudinal data based on the Norwegian population. By connecting industry to high quality biosamples, a comprehensive network of national health registries, and depth information about health and disease we offer unparalleled access to this population.

Lifandis advances disease understanding and leads to better healthcare products.

Lifandis is owned by the Norwegian University of Science and Technology, the Central Norway Health Authority and the Nord-Trøndelag County.

The company changed its name from Hunt Biosciences AS to Lifandis AS as of April 1, 2014.

For more info, please check www.lifandis.com

HÅRklinikken UK 2013_0515

Wed, 15 May 2013 22:57:22 GMT

HÅRklinikken UK 2013_0515

HÅRklinikken DK 2013_0515

Wed, 15 May 2013 22:57:13 GMT

HÅRklinikken DK 2013_0515

Roskilde - Dansk Fløde - Høretelefonkoncert

Mon, 04 Mar 2013 22:34:58 GMT

Peter Rasborg, BDO

Fri, 21 Sep 2012 12:33:22 GMT

Peter Rasborg fortæller om sin passion for revision og om at få tingene til at gå op i en højere enhed gennem hans evne til at få overblik og hjælpe med at finde de rigtige løsninger.

BGI, the world’s largest genomics organization, opened on February 10th its...

Mon, 13 Feb 2012 11:35:39 GMT

BGI, the world’s largest genomics organization, opened on February 10th its first European Genome Research Center located in Copenhagen Bio Science Park (COBIS). This research center is about 1,200 square meters and equipped with 10 Illumina HiSeq 2000 sequencers. The center aims to establish collaborations to better accelerate the innovation and development of genomics research and applications in health care, agriculture, bioenergy and other related areas in Europe.

BGI Chairman Huanming Yang has expressed his appreciation to the Danish government and the scientific partner in Denmark. He said, “Nothing would have been made possible by BGI without the full understanding, continuous encouragement and firm support from our supervisors, colleagues and friends in both the academic and industrial communities in Denmark since the very beginning until now. BGI’s leaders and staff have been successively educated and trained in Denmark from the past to present. It is the strong tie between BGI and Denmark both culturally and scientifically which led BGI’s choice to establish the first European Genome Research Center of BGI in Copenhagen, Denmark.”

According to Ning Li, Director of BGI Europe, the genome research center grants from the Danish National Advanced Technology Foundation (HTF). Two integrated projects will be initiated in this center, one is to identify previously unknown cancer pathogens that will lead to the development and patenting of commercial vaccines and the other is to establish a unique catalogue of the millions of variations in Dane’s DNA by finishing 1% Dane’s Genome Sequencing. The genome atlas will serve as the foundation for new studies that will cast light on the hereditary causes for a number of common diseases, as well as the treatment and prevention.

BGI opening 2012

Mon, 12 Sep 2011 23:35:05 GMT

On March 3, 2011, a new research center--Danish Platform for Large-scale Sequencing and Bioinformaticsis to be funded with DKK 170 million by Danish National Advanced Technology Foundation (DKK 84 million), BGI (DKK 60 million) and other partners. This center aims to support development of cancer vaccines and Danish genome research. There are two projects in this platform: One project is to identify previously unknown pathogens that will lead to the development and patenting of commercial vaccines. The second is to establish a unique catalogue of the millions of variations in Danes' DNA. BGI Europe (an overseas branch of BGI) situated at Copenhagen Bio Science Park (COBIS) will play an important role in the disease prevention and genome research.

The following article is quoted from the news release of University of Copenhagen:
http://news.ku.dk/all_news/2011/2011.3/majorgranttosupportdevelopmentofcancervaccine/

Pharmacosmos CRO

Fri, 09 Sep 2011 16:45:51 GMT

Pharmacosmos CRO
Unique access to optimized global development
We offer unique access to optimized global medical product development for European biotech and pharmaceutical companies:
• Integrated development planning through a senior development team
• Patient recruitment in key global geographies through validated partners
• Flexibility and agility of an SME
• Global regulatory track record
• Single point of contact
We have a track record for bringing new products from concept through to commercialization together with our dedicated and validated partner network.
We have achieved registrations in more than 50 countries and registration times of less than 3 years from first-in-human to first registration.
Our team provides the optimal solution to secure your specific milestones and regulatory objectives to satisfy your investors. What ever your needs, we always focus on delivering high quality solutions

Our approach
Optimizing global medical product development
Our approach is to keep an in-house team of development executives to handle the strategic planning and manage plan execution. Execution is done through a global network of validated and audited partners.
For European biotech companies this approach maximize the value creation through
• Easy access to a seasoned VP team of developers
• Track record from CMC through to commercialization
• Insight and experience to obtain key regulatory buy in from FDA and EMA
• Patient recruitment in key global geographies
For European pharmaceutical companies we add value through
• Combining European, US and Indian core competences when executing your studies
• Guiding and managing functional outsourcing of clinical development services
• Obtaining and maintaining global registrations through our network
This way we accelerate clinical development at reduced cost, add flexibility, and help companies expand their commercialization to the global market place.

Our team
Identifying the most optimal plan to achieve your specific development goals
Pharmacosmos CRO offers access to a seasoned VP team of developers spanning from CMC through to commercialization. Together, our team helps develop the most optimal plan to secure your specific development goals.

Primary contact
Jeppe Skytte  Sales and Business Development Manager MSc, PhD

Our VP team
Claes Christian Strom  Vice President, Medical Affairs MD, PhD, BBA

Lars Lykke Thomsen  Vice President, Chief Medical Officer MD, PhD, DMSc

Kim Nordfjeld   Vice President, Quality and Registration PhD Pharmacy

Jens Fabricius  Vice President, Marketing and Business Operations BCommerce, EMBA

Robert Guglielmetti  Executive Vice President, Chief Financial Officer MSc Accounting

To learn more about Pharmacosmos CRO and our ability to secure your development milestone, please contact Jeppe Skytte:
Jeppe Skytte  Sales and Business Development Manager MSc, PhD  T: +45 59 48 59 85 (direct) T: +45 22 84 26 56 (mobile) E: jsk@pharmacosmos.com
Pharmacosmos CRO offices
Pharmacosmos CRO A/S Roervangsvej 30 DK-4300 Holbaek Denmark
Learn more about Pharmacosmos
Visit our corporate website: www.pharmacosmos.com

novo seeds

Wed, 31 Aug 2011 18:06:08 GMT

The pre-seed program supports early stage projects based on ideas and results with commercial potential. Funding is given as grants in the same manner as other grants awarded by the Novo Nordisk Foundation.

The seed fund aims at supporting more advanced projects and will operate on commercial terms, i.e. support is given to projects and companies in exchange for ownership or other rights to the companies/projects. Typically, the seed program will invest in newly formed companies that are too early in their development stage to be supported by Novo A/S’ venture capital or other international investors.

http://www.novo.dk/composite-364.htm

NovVac 2011

Wed, 31 Aug 2011 15:52:26 GMT

novo seeds - long version

Mon, 29 Aug 2011 12:34:00 GMT

Novo Seeds
Novo Seeds is a life science supporting program launched by the Novo Nordisk Foundation and Novo A/S. Novo Seeds has two components, a pre-seed funding capacity and a seed financing fund. Both aim at identifying and developing the unexplored commercial potential present in academic and early stage applied research projects at universities and biotech companies within life science in Scandinavia.
The pre-seed program supports early stage projects based on ideas and results with commercial potential. Funding is given as grants in the same manner as other grants awarded by the Novo Nordisk Foundation.
The seed fund aims at supporting more advanced projects and will operate on commercial terms, i.e. support is given to projects and companies in exchange for ownership or other rights to the companies/projects. Typically, the seed program will invest in newly formed companies that are too early in their development stage to be supported by Novo A/S’ venture capital or other international investors.
About Novo Seeds
Novo Seeds was launched in September 2007 as a new initiative from Novo A/S and the Novo Nordisk Foundation to provide funding for early stage projects and seed financing of new life science companies in Scandinavia. Through the Novo Seeds programs, the Novo Group can support all stages of life science development, from basic research grants from the Novo Nordisk Foundation through seed funding to venture financing from Novo A/S.
Novo Seeds is based within the Novo A/S organization, and has a large network within the Scandinavian and international biotech industry. We strive to leverage this extensive network to the benefit of our portfolio companies and the projects we support through our pre-seed grants.

Novo Seeds' focus
The pre-seed program is aimed at providing support for commercially interesting projects, typically originating from academic research institutions in Scandinavia, which are too early for seed investments. The pre-seed grants can be used for additional proof-of-principle studies, supportive investigations, and freedom to operate analysis or other activities which are required to prepare the project for a seed financing round.
The seed program focuses on Scandinavian life science companies. Our primary focus is projects for diagnosis, control, treatment, and prevention of disease. Novo Seeds aims to play a leading role in the financing, but welcomes syndication with other investors in its portfolio companies. In addition to financial support, Novo Seeds provides organisational, strategic and other assistance, typically anchored in one or more board seats in the portfolio companies.

novo seeds video - short version

Mon, 29 Aug 2011 12:03:26 GMT

http://www.novo.dk/composite-364.htm

NovVac 2011

Mon, 29 Aug 2011 11:34:46 GMT

NovVac is a danish biotech company that has developed an algorithm for identification of antigens that can be used for vaccine development

novo seeds - trailer

Mon, 29 Aug 2011 11:20:18 GMT

Novo Seeds is a life science supporting program launched by the Novo Nordisk Foundation and Novo A/S. Novo Seeds has two components, a pre-seed funding capacity and a seed financing fund. Both aim at identifying and developing the unexplored commercial potential present in academic and early stage applied research projects at universities and biotech companies within life science in Scandinavia.
The pre-seed program supports early stage projects based on ideas and results with commercial potential. Funding is given as grants in the same manner as other grants awarded by the Novo Nordisk Foundation.
The seed fund aims at supporting more advanced projects and will operate on commercial terms, i.e. support is given to projects and companies in exchange for ownership or other rights to the companies/projects. Typically, the seed program will invest in newly formed companies that are too early in their development stage to be supported by Novo A/S’ venture capital or other international investors.
About Novo Seeds
Novo Seeds was launched in September 2007 as a new initiative from Novo A/S and the Novo Nordisk Foundation to provide funding for early stage projects and seed financing of new life science companies in Scandinavia. Through the Novo Seeds programs, the Novo Group can support all stages of life science development, from basic research grants from the Novo Nordisk Foundation through seed funding to venture financing from Novo A/S.
Novo Seeds is based within the Novo A/S organization, and has a large network within the Scandinavian and international biotech industry. We strive to leverage this extensive network to the benefit of our portfolio companies and the projects we support through our pre-seed grants.

Dr Eugen-Olsen and his team in Africa

Tue, 21 Jun 2011 22:07:20 GMT

A movie on the EU-funded project on providing better treatment to TB infected. Produced by BioLogicMedia